EDGAR MILLER 3rd

Dr. EDGAR MILLER 3rd


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2005 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
E3EDGAR MILLER 3rd
EDGAR MILLER 3rd
PRPastor-Barriuso Roberto
Pastor-Barriuso Roberto
DDDarshan Dalal
Darshan Dalal
RRRudolph A. Riemersma
Rudolph A. Riemersma
LALawrence J. Appel
Lawrence J. Appel
EGEliseo Guallar
Eliseo Guallar
Experimental models and observational studies suggest that vitamin E supplementation may prevent cardiovascular disease and cancer. However, several trials of high-dosage vitamin E supplementation showed non–statistically significant increases in total mortality. To perform a meta-analysis of the dose–response relationship between vitamin E supplementation and total mortality by using data from randomized, controlled trials. 135 967 participants in 19 clinical trials. Of these trials, 9 tested vitamin E alone and 10 tested vitamin E combined with other vitamins or minerals. The dosages of vitamin E ranged from 16.5 to 2000 IU/d (median, 400 IU/d). PubMed search from 1966 through August 2004, complemented by a search of the Cochrane Clinical Trials Database and review of citations of published reviews and meta-analyses. No language restrictions were applied. 3 investigators independently abstracted study reports. The investigators of the original publications were contacted if required information was not available. 9 of 11 trials testing high-dosage vitamin E (≥400 IU/d) showed increased risk (risk difference > 0) for all-cause mortality in comparisons of vitamin E versus control. The pooled all-cause mortality risk difference in high-dosage vitamin E trials was 39 per 10 000 persons (95% CI, 3 to 74 per 10 000 persons; P = 0.035). For low-dosage vitamin E trials, the risk difference was −16 per 10 000 persons (CI, −41 to 10 per 10 000 persons; P > 0.2). A dose–response analysis showed a statistically significant relationship between vitamin E dosage and all-cause mortality, with increased risk of dosages greater than 150 IU/d. High-dosage (≥400 IU/d) trials were often small and were performed in patients with chronic diseases. The generalizability of the findings to healthy adults is uncertain. Precise estimation of the threshold at which risk increases is difficult. High-dosage (≥400 IU/d) vitamin E supplements may increase all-cause mortality and should be avoided.

1 May 2012 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
SJStephen P. Juraschek
Stephen P. Juraschek
EGEliseo Guallar
Eliseo Guallar
LALawrence J Appel
Lawrence J Appel
E3EDGAR MILLER 3rd
EDGAR MILLER 3rd
Background: In observational studies, increased vitamin C intake, vitamin C supplementation, and higher blood concentrations of vitamin C are associa

1 April 2013 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
SJStephen P. Juraschek
Stephen P. Juraschek
LALawrence J. Appel
Lawrence J. Appel
CACheryl A.M. Anderson
Cheryl A.M. Anderson
E3EDGAR MILLER 3rd
EDGAR MILLER 3rd

1 August 2010 in The American Journal of Cardiology
Verified
Journal Article
Closed access
E3EDGAR MILLER 3rd
EDGAR MILLER 3rd
SJStephen P. Juraschek
Stephen P. Juraschek
PRPastor-Barriuso Roberto
Pastor-Barriuso Roberto
LBLydia A. Bazzano
Lydia A. Bazzano
LALawrence J. Appel
Lawrence J. Appel
EGEliseo Guallar
Eliseo Guallar

10 September 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
SJStephen P. Juraschek
Stephen P. Juraschek
JHJiun-Ruey Hu
Jiun-Ruey Hu
JCJennifer L. Cluett
Jennifer L. Cluett
AIAnthony Ishak
Anthony Ishak
CMCarol Mita
Carol Mita
KMKenneth J. Mukamal
Kenneth J. Mukamal
Whether intensive blood pressure–lowering treatment in adults with hypertension causes orthostatic hypotension is unclear. This systematic review and individual participant-based meta-analysis exam... Background: Although intensive blood pressure (BP)–lowering treatment reduces risk for cardiovascular disease, there are concerns that it might cause orthostatic hypotension (OH). Purpose: To exami...

1 June 2009 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
E3EDGAR MILLER 3rd
EDGAR MILLER 3rd
SJStephen P. Juraschek
Stephen P. Juraschek
LALawrence J Appel
Lawrence J Appel
MMMadhavi Madala
Madhavi Madala
CACheryl Am Anderson
Cheryl Am Anderson
EGEliseo Guallar
Eliseo Guallar
Chronic kidney disease is a major worldwide problem. Although epidemiologic and experimental studies suggest that n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation may prevent or slow the progression of kidney disease, evidence from clinical trials is inconsistent. The objective was to combine evidence from controlled clinical trials to assess the effect of n-3 LCPUFA supplementation on the change in urine protein excretion (UPE) and on glomerular filtration rate (GFR). We performed a meta-analysis of clinical trials that tested the effect of n-3 LCPUFA supplementation on UPE, a marker of kidney damage, and on GFR, a marker of kidney function. A random-effects model was used to pool SD effect size (Cohen's d) across studies. Seventeen trials with 626 participants were included in the meta-analysis. Most trials focused on patients with a single underlying diagnosis: IgA nephropathy (n = 5), diabetes (n = 7), or lupus nephritis (n = 1). The dose of n-3 LCPUFAs ranged from 0.7 to 5.1 g/d, and the median follow-up was 9 mo. In the pooled analysis, there was a greater reduction in UPE in the n-3 LCPUFA group than in the control group: Cohen's d for all trials was -0.19 (95% CI: -0.34, -0.04; P = 0.01). In a patient with 1 g UPE/d , this corresponds to a reduction of 190 mg/d. Effects on GFR were reported in 12 trials. The decline in GFR was slower in the n-3 LCPUFA group than in the control group, but this effect was not significant (0.11; 95% CI: -0.07, 0.29; P = 0.24). In our meta-analysis, use of n-3 LCPUFA supplements reduced UPE but not the decline in GFR. However, small numbers of participants in trials, different methods of assessing proteinuria and GFR, and inconsistent data reporting limit the strength of these conclusions. Large, high-quality trials with clinical outcomes are warranted.